Our primary objective in this study was to determine the differences in inflammatory profile between patients with high risk for obstructive sleep apnea (OSA) versus low risk in a patient population undergoing cardiac rehabilitation and to evaluate the effect of 4 weeks of rehabilitation on cytokine levels in the 2 groups. A total of 20 consecutive patients were screened using the Berlin questionnaire to determine high and low risk of OSA. Of the 20 total consecutive patients, 3 patients did not consent to participate and 1 did not get cytokine analysis. Of the remaining 16 patients (8 men and 8 women), 8 (50%) patients were found to have high risk for OSA as predicted by the Berlin questionnaire. Men predominated the high-risk group (75%). There was a trend of increased cytokine load in the high-risk group; however, it did not reach statistical significance except for monocyte chemoattractant protein-1 (P value=0.02). A significant reduction was noted in cytokine levels after 4 weeks of rehabilitation in the group with OSA, which was statistically significant (P value<0.5). The high-risk group patients had elevated cytokine levels, especially monocyte chemoattractant protein-1. Further, a significant reduction in cytokine levels was noted in the high-risk group after 4 weeks of rehabilitation.
Get full access to this article
View all access options for this article.
References
1.
BoisvertWA, SantiagoR, CurtissLK, TerkeltaubRA. 1998. A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor-deficient mice. J Clin Invest, 101:353–363.
2.
BoringL, GoslingJ, ClearyMothers.1998. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature, 394:894–897.
3.
CharoIF, TaubmanMB. 2004. Chemokines in the pathogenesis of vascular disease. Circ Res, 95:858–866.
4.
de LemosJA, MorrowDA, SabatineMS, MurphySA, GibsonCM, AntmanEM, McCabeCH, CannonCP, BraunwaldE. 2003. Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation, 107:690–695.
5.
ElenkovIJ, ChrousosGP. 1999. Stress hormones, Th1/Th2 patterns, pro/anti- inflammatory cytokines and susceptibility to disease. Endocrinol Metab, 10:359–368.
6.
FearonDT, LocksleyRM. 1996. The instructive role of innate immunity in the acquired immune response. Science, 272:50–53.
7.
FreemantleN, ClelandJothers.1997. Beta blockade after myocardial infarction: Systematic review and meta regression analysis. BMJ, 318:1730–1737.
8.
FurukawaY, MatsumoriA, OhashiN, ShioiT, OnoK, HaradaA, MatsushimaK, SasayamaS. 1999. Anti–monocyte chemoattractant protein-1/monocyte chemotactic and activating factor antibody inhibits neointimal hyperplasia in injured rat carotid arteries. Circ Res, 84:306–314.
9.
GamiAS, PressmanGothers.2004. Association of atrial fibrillation and obstructive sleep apnea. Circulation, 110:364–367.
10.
GersztenRE, Garcia-ZepedaEA, LimY-C, YoshidaM, DingHA, GimbroneMA.Jr., LusterAD, LuscinskasFW, RosenzweigA. 1999. MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature, 398:718–723.
11.
GoldhammerEothers.2005. Exercise training modulates cytokines activity in coronary heart disease patients. Int J Cardiol, 100:93–99.
12.
GuL, OkadaY, ClintonSothers.1998. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low-density lipoprotein-deficient mice. Mol Cell, 2:275–281.
13.
HanssonG, LibbyP. 1996. The role of the lymphocyte. FusterV, RossR, TopolE. Atherosclerosis and coronary artery disease. New York, NY: Lippincott-Raven, 557–568.
14.
HorvathC, WeltFGP, NedelmanM, RaoP, RogersC. 2002. Targeting CCR2 or CD18 inhibits experimental in-stent restenosis in primates. Inhibitory potential depends on type of injury and leukocytes targeted. Circ Res, 90:488–494.
15.
JavaheriS. 2006. Sleep disorders in systolic heart failure: a prospective study of 100 male patients. Int J Cardiol, 106:21–28.
16.
KadoglouNP, IliadisFothers.2007. The anti-inflammatory effects of exercise training in patients with type 2 diabetes mellitus. Eur J Cardiovasc Prev Rehabil, 14,6:837–843.
17.
MilleronOothers.2004. Benefits of obstructive sleep apnoea treatment in coronary artery disease: a long-term follow-up study. Eur Heart J, 25:728–734.
18.
Mohamed-AliV, BulmerKothers.2000. Beta adrenergic regulation of proinflammatory cytokines in humans. Int J Obes Relat Metab Disord, 24,Suppl:5154–5155.
19.
MooeT, FranklinKA, HolmstromKothers.2001. Sleep-disordered breathing and coronary artery disease: long-term prognosis. Am J Respir Crit Care Med, 164:1910–1913.
20.
MooeT, RabbenT, WiklundU, FranklinKA, ErikssonP. 1996. Sleep-disordered breathing in men with coronary artery disease. Chest, 109:659–663.
21.
MosmannTR, SadS. 1996. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today, 17:138–146.
22.
NetzerNC, StoohsRA, NetzerCMothers.1999. Using the Berlin Questionnaire to identify patients at risk for the sleep apnea syndrome. Ann Intern Med, 131:485–491.
23.
OhgaE, TomitaT, WadaHothers.2003. Effects of obstructive sleep apnea on circulating ICAM-1, IL-8, and MCP-1. J Appl Physiol, 94:179–184.
24.
PekerYothers.1999. An independent association between obstructive sleep apnea and coronary artery disease. Eur Respir J, 14:179–184.
25.
PepperellJC, Ramdassingh-DowS, CrosthwaiteN, MullinsR, JenkinsonC, StradlingJR, DaviesRJ. 2002. Ambulatory blood pressure after therapeutic and subtherapeutic nasal continuous positive airway pressure for obstructive sleep apnoea: a randomised parallel trial. Lancet, 359:204–210.
26.
PetersenAMW, PedersenBK. 2005. The anti-inflammatory effects of exercise. J Appl Physiol, 98:1154–1162.
27.
RossR. 1995. Growth regulatory mechanisms and formation of the lesions of atherosclerosis. Ann NY Acad Sci, 748:1–4.
28.
SchaferFothers.1999. Obstructive sleep apnea as a risk marker in coronary artery disease. Cardiology, 92:79–84.
29.
ShamsuzzamanAS, WinnickiM, LanfranchiPothers.2002. Elevated C-reactive protein in patients with obstructive sleep apnea. Circulation, 105:2462–2464.
30.
SharmaS, ParkerAT. 2010. Prevalence of undetected OSA in patients undergoing cardiac rehabilitation. J Cardiopulm Rehabil Prev 2010[Epub ahead of print]10.1097/HCR.0b013e318203339b.
31.
TeramotoS, YamamotoH, OuchiY. 2003. Increased C-reactive protein and increased plasma interleukin-6 may synergistically affect the progression of coronary atherosclerosis in obstructive sleep apnea syndrome [letter]Circulation, 107:E40.
32.
VgontzasAN, PapanicolaouDA, BixlerEOothers.2002. Sleep apnea and daytime sleepiness and fatigue: relation to visceral obesity, insulin resistance, and hypercytokinemia. J Clin Endocrinol Metab, 85:1151–1158
33.
YokoeT, MinoguchiK, MatsuoHothers.2003. Elevated levels of C-reactive protein and interleukin-6 in patients with obstructive sleep apnea syndrome are decreased by nasal continuous positive airway pressure. Circulation, 107:1129–1134.
